After coming up short in an attempt to find a niche for its COVID vaccine, Valneva is focused on launching its new chikungunya virus vaccine Ixchiq.
VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue...
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain (France), March 25, 2024 “ Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration...
Saint-Herblain (France), March 21, 2024 “ Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®,...
Total revenues of ‚¬153.7 million, including product sales of ‚¬144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26%Excluding COVID-19 vaccine sales, product...
on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 million to $206.45 million) in 2024, as it anticipates sales growth of its travel vaccines and the launch of Ixiaro.
Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine...
VALNEVA Declaration of shares and voting rights - February 29, 2024
Valneva to Present at Upcoming TD Cowen Healthcare Investor Conferences